Physician profile
Steven J Ma
NPI 1609864669
$10,759.46
in general payments reported to CMS, 2019-2025
39 companies · $2,082 in 2025
The $2,082 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,178 · 2020: $1,669 · 2021: $1,837 · 2022: $1,176 · 2023: $1,334 · 2024: $1,483 · 2025: $2,082.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,899.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,898.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,546.42 | 2020-2025 | |
| Novo Nordisk INC | $1,442.32 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $1,120.29 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Astrazeneca Pharmaceuticals LP | $978.07 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Amgen INC. | $904.91 | 2019-2024 | Repatha, Prolia, Evenity |
| Pfizer INC. | $622.29 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $526.24 | 2019-2025 | Xifaxan, Trulance |
| Glaxosmithkline, LLC. | $514.10 | 2019-2024 | Shingrix, Arexvy, Trelegy Ellipta |
| Supernus Pharmaceuticals, INC. | $350.79 | 2019-2024 | Qelbree, Qelbree |
| Astellas Pharma US INC | $320.60 | 2019-2024 | Veozah |
| Kowa Pharmaceuticals America, INC. | $283.74 | 2019-2022 | |
| Allergan, INC. | $257.35 | 2019-2020 | |
| Exact Sciences Corporation | $166.01 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Sanofi-Aventis U.S. LLC | $157.76 | 2019-2021 | |
| Vanda Pharmaceuticals INC. | $145.43 | 2025 | Fanapt |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Ma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.